WO2004099781A3 - Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g - Google Patents

Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g Download PDF

Info

Publication number
WO2004099781A3
WO2004099781A3 PCT/EP2004/004278 EP2004004278W WO2004099781A3 WO 2004099781 A3 WO2004099781 A3 WO 2004099781A3 EP 2004004278 W EP2004004278 W EP 2004004278W WO 2004099781 A3 WO2004099781 A3 WO 2004099781A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
rdc1
diseases
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/004278
Other languages
English (en)
Other versions
WO2004099781A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2004099781A2 publication Critical patent/WO2004099781A2/fr
Publication of WO2004099781A3 publication Critical patent/WO2004099781A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un récepteur RDC1 humain qui est associé aux maladies cardiovasculaires, aux maladies dermatologiques, aux maladies du système endocrinien et aux troubles hormonaux, aux troubles métaboliques, aux maladies inflammatoires, aux maladies gastro-intestinales et hépatiques, ainsi qu'aux maladies hématologiques, respiratoires, neurologiques et urologiques. De plus, l'invention concerne des méthodes de criblage qui permettent d'identifier des composés utilisés dans le traitement ou la prévention des maladies cardiovasculaires, des maladies dermatologiques, des maladies du système endocrinien et des troubles hormonaux, des troubles métaboliques, des maladies inflammatoires, des maladies gastro-intestinales et hépatiques, ainsi que des maladies hématologiques, respiratoires, neurologiques et urologiques. Par ailleurs, l'invention concerne des composés qui se lient au récepteur RDC1 et/ou qui activent ou inhibent son activité ainsi que des compositions pharmaceutiques contenant ces composés.
PCT/EP2004/004278 2003-05-05 2004-04-22 Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g WO2004099781A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010113.3 2003-05-05
EP03010113 2003-05-05

Publications (2)

Publication Number Publication Date
WO2004099781A2 WO2004099781A2 (fr) 2004-11-18
WO2004099781A3 true WO2004099781A3 (fr) 2005-06-02

Family

ID=33427037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/004278 WO2004099781A2 (fr) 2003-05-05 2004-04-22 Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g

Country Status (1)

Country Link
WO (1) WO2004099781A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678891B2 (en) * 2005-04-21 2010-03-16 Chemocentryx, Inc. Antibodies that bind CCX-CKR2
WO2010141986A1 (fr) * 2009-06-09 2010-12-16 Mabdesign Pty Ltd Nouveaux anticorps et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197069B1 (en) * 1997-12-08 2001-03-06 Smithkline Beecham Corporation Adrenomedullin receptor polynucleotides
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
WO2004058051A2 (fr) * 2002-12-20 2004-07-15 The Institute For Systems Biology Genes regules par l'androgene et utilisations dans le diagnostic, le pronostic et le traitement de troubles neoplasiques de la prostate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197069B1 (en) * 1997-12-08 2001-03-06 Smithkline Beecham Corporation Adrenomedullin receptor polynucleotides
WO2002061087A2 (fr) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
WO2004058051A2 (fr) * 2002-12-20 2004-07-15 The Institute For Systems Biology Genes regules par l'androgene et utilisations dans le diagnostic, le pronostic et le traitement de troubles neoplasiques de la prostate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAW NORMAN M ET AL: "Characterization of the G-protein linked orphan receptor GPRN1/RDC1", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 201, no. 1, 1994, pages 458 - 465, XP002146891, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2004099781A2 (fr) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2004097421A3 (fr) Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
WO2005095973A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54)
WO2005040828A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 49 couple aux proteines g (gpr49)
WO2004099782A3 (fr) Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2005050225A3 (fr) Outils de diagnostic et de traitement de maladies associees au recepteur 84 couple aux proteines g (gpr84)
WO2005074969A3 (fr) Diagnostics et traitements de maladies associees au recepteur nucleaire humain nr4a1 (nr4a1)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2004099783A3 (fr) Diagnostics et therapies destines a des maladies associees au recepteur ltb4 (ltb4) couple a la proteine g
WO2004099781A3 (fr) Approches diagnostique et therapeutique des maladies associees au recepteur rdc1 (rdc1) couple a une proteine g
WO2005095984A3 (fr) Compositions diagnostiques et therapeutiques pour des maladies associees au recepteur adrenergique alpha 2a couple a la proteine g (adra2a)
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2005040829A3 (fr) Agents de diagnostic et de traitement des maladies associees au recepteur 17 couple aux proteines g (gpr17)
WO2004106935A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103)
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2005108998A3 (fr) Methodes de diagnostic et de traitement de maladies associees au recepteur couple aux proteines g adrenergique beta-3 (adrb3)
WO2004086034A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2004081563A3 (fr) Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a)
WO2005059504A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g gpr34 (gpr34)
WO2005073729A3 (fr) Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)
WO2004099772A3 (fr) Methodes diagnostiques et therapeutiques pour les maladies associees au recepteur agtr1a couple aux proteines g (agtr1a)
WO2004082571A3 (fr) Diagnostics et therapies pour maladies associees au recepteur 86 couple a la proteine g (gpr86)
WO2005040824A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 24 couple a la proteine g (gpr24)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase